118 S1852 RS: Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023 U.S. Senate 2023-09-06 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

IICalendar No. 201118th CONGRESS1st SessionS. 1852IN THE SENATE OF THE UNITED STATESJune 7, 2023Mr. Scott of South Carolina (for himself, Mr. Booker, and Mr. Warnock) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and PensionsSeptember 6, 2023Reported by Mr. Sanders, without amendmentA BILLTo amend the Public Health Service Act to reauthorize a sickle cell disease prevention and treatment demonstration program.

1.

Short title

This Act may be cited as the Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023.

2.

Sickle cell disease treatment prevention and treatment

(a)

In general

Section 1106(b) of the Public Health Service Act (42 U.S.C. 300b–5(b)) is amended—(1)in paragraph (1)(A)(iii), by striking prevention and treatment of sickle cell disease and inserting treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease;(2)in paragraph (2)(D), by striking prevention and treatment of sickle cell disease and inserting treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease;(3)in paragraph (3)—(A)in subparagraph (A), by striking enter into a contract with and inserting make a grant to, or enter into a contract or cooperative agreement with,; and(B)in subparagraph (B), in each of clauses (ii) and (iii), by striking prevention and treatment of sickle cell disease and inserting treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease; and(4)in paragraph (6), by striking $4,455,000 for each of fiscal years 2019 through 2023 and inserting $8,205,000 for each of fiscal years 2024 through 2028.(b)

Sense of Congress

It is the sense of Congress that further research should be undertaken to expand the understanding of the causes of, and to find cures for, heritable blood disorders, including sickle cell disease.

September 6, 2023Reported without amendment